| Literature DB >> 30009170 |
Li Lu1, Xiaodong Sun2, Yating Qin1, Xiaomei Guo1.
Abstract
Cardiovascular diseases (CVDs) are considered to be the predominant cause of death in the world. Chinese herb medicines (CHMs) have been widely used for the treatment of CVDs in Asian countries for thousands of years. One reason of high efficacy of CHMs in treating CVDs is attributed to their inhibition in atherosclerosis (AS) development, a critical contributor to CVDs occurrence. Cumulative studies have demonstrated that CHMs alleviate atherogenesis via mediating pathophysiologic events involved in AS. However, there is deficiency in the summaries regarding antiatherogenic signal pathways regulated by CHMs. In this review, we focus on the signal cascades by which herb medicines and relevant extractives, derivatives, and patents improve proatherogenic processes including endothelium dysfunction, lipid accumulation, and inflammation. We mainly elaborate the CHMs-mediated signaling pathways in endothelial cells, macrophages, and vascular smooth muscle cells of each pathogenic event. Moreover, we briefly describe the other AS-related factors such as thrombosis, autophagy, immune response, and noncoding RNAs and effects of CHMs on them in the way of cascade regulation, which is helpful to further illustrate the molecular mechanisms of AS initiation and progression and discover newly effective agents for AS management.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30009170 PMCID: PMC6020658 DOI: 10.1155/2018/5392375
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
The classification of compounds from CHMs with anti-AS roles.
| Category | Compound |
|---|---|
| Terpenoid | Saikosaponin-a, tanshinone IIA, tanshindiol C, ginkgolide B, andrographolide, paeoniflorin, cryptotanshinone, danshenol A, dihydrotanshinone I, celastrol, 1, 6-di-O-caffeoyl- |
| Saponin | Xinxuekang, compound K, ginsenoside Rb1, gypenoside XVII, Ginsenoside F1, glycyrrhizic acid, Diosgenin, Elatoside C, Celosin |
| Alkaloid | Berberine, trichosanatine, ligustrazine, coptisine, |
| Flavonoid | Kuwanon G, myricitrin, dihydromyricetin, isoquercitrin, icariin, apigenin, isohamnetin, baicalin, hydroxysafflor yellow A, hyperoside, quercetin, wogonin, procyanidin, dracocephalum moldavica, rumex acetose L, delphinidin-3-glucoside, gossypetin |
| Isoflavonoid | Puerarin, Biochanin-A |
| Phenolic | Danshensu, paeonol, salvianolic acid B, luteolin |
| Stilbenoid | Pterostilbene, resveratrol |
| Iridoid | Geniposide, Genipin |
| Diarylheptanoid | Curcumin |
Figure 1The pathogenesis of atherosclerosis. The endothelial dysfunction, inflammation, and lipid dysbolism induce excessive cholesterol disposition and leukocytes accumulation into the vascular intima. Then macrophages and neutrophil secret cytokines and T cells release immune regulatory factors, which promote AS progression. Moreover, macrophages uptake cholesterols and transform into foam cells, facilitating the formation of lipid core. VSMCs migrate to the subendothelium and release extracellular matrix, leading to the formation of fibrous cap and vascular remolding. In addition, platelets are activated and aggregate to the injured vascular endothelium, contributing to the thrombosis.
Figure 2The signaling pathways by which CHMs alleviate lipid accumulation in macrophages.
Figure 3The pathway mechanisms underlying CHMs improve lipid metabolism in liver cells.
Figure 4The effects at molecular level produced by CHMs in the attenuation of ECs apoptosis. ELCAS: Ligusticum chuanxiong and Angelica sinensis; XMJ: Xinmaijia; WXD: Wenxin decoction; and TSG: 2,3,5,4'-Tetrahydroxystilbene-2-o-β-D-glucoside.
The signal pathways underlying CHMs inhibit the thrombosis.
| Ingredient | Herb medicine | Object | Stimulus | Role | related pathway |
|---|---|---|---|---|---|
| 1, 6-di-O-caffeoyl- | Callicarpa nudiflora Hook | Platelet | ADP, AA |
| PI3K/Akt/GSK3 |
| Atractylenolide | Atractylodes macrocephala | Platelet | ADP, collagen, thrombin | platelet aggregation and secretion↓ | p38, PI3K/Akt |
| Andrographolide | Andrographis paniculata | Platelet | Collagen | platelet aggregation, Ca2+, TxB2↓ | eNOS/NO/sGC/cGMP, PI3K/Akt/p38/cPLA2, PLC |
| platelet aggregation, Ca2+↓ | eNOS/NO/sGC/cGMP, p38/ROS/IKK | ||||
| Gomisin J | Schisandra chinensis | EC | None | eNOS, NO↑ | Ca2+/CaMI, PI3K/Akt |
|
| Curcuma Wenyujin | EC | None | eNOS, NO↑ | PI3K/Akt |
| Puerarin | Pueraria lobata | EC | TNF- | eNOS, NO↑ | ER/PI3K/Akt, CaMKII/AMPK |
| Tanshinone IIA | Salvia miltiorrhiza Bunge | Macrophage | Ox-LDL | TF↓ | ROS/NF- |
| Platelet | None | Platelet activation↓ | ER | ||
| Platelet | ADP | Platelet activation↓ | ERK-2 | ||
| Xuezhikang | Red yeast rice | Macrophage | Ox-LDL | TF↓, SOD↑ | NOX/ROS/ERK1/2/NF- |
| Gypenoside XLIX | Gynostemma pentaphyllum | Macrophage | LPS | TF↓ | PPAR- |
| Salvianolic acid B | Salvia miltiorrhiza Bunge | EC | TNF- | PAI-1↓ | ERK1/2/AP-1 (NF- |
The signal pathways responsible for CHMs-induced regulation of autophagic processes.
| Agent | Herb medicine | Object | Stimulus | Role | related pathway |
|---|---|---|---|---|---|
| Delphinidin-3-glucoside | Grape seed | EC | Ox-LDL | Cell viability ↑, apoptosis↓; LC3II↑, p62↓ | AMPK/SIRT1 |
| Gossypetin | Hibiscus | EC | Ox-LDL | LDH, cleaved caspase-3 and PARP-1↓; LC3II and Beclin-1↑, p62↓ | PTEN/class I PI3k/Akt, class III PI3K/Beclin-1 |
| Pterostilbene | Blueberry | EC | Ox-LDL | TUNEL-positive cell↓; LC3II↑, p62↓ | Ca2+/CaMKK |
| Resveratrol | Grape | EC | TNF- | ICAM-1, COX-2, MMP-9↓; LC3II↑, p62↓ | ATP/cAMP/AMPK/SIRT1 |
| EC | Ox-LDL | Cell vability and SOD↑; LC3II/LC3I↑, p62↓ | AMPK/SIRT1 | ||
| Elatoside C | Aralia elata Seem | EC | Ox-LDL | TUNEL-positive nuclei, Bax, caspase-9 and -3, ROS↓, Bcl-2↑; LC3II and Beclin-1↑, p62↓ | FoxO1/Beclin-1, LOX-1/NOX/ROS/Caspase |
| Berberine | Coptis chinensis | macrophage | Ox-LDL | MIP-1 | AMPK/mTOR |
| None | ABCA1, ROS↑; LC3II/LC3I↑, p62↓ | PI3k/Akt/mTOR | |||
| Arglabin | Artemisia glabella | macrophage | LPS | IL-1 | unknown |
| Celosins | Celosia argentea L. | macrophage | Ox-LDL | CD36, SR-A1↓, ABCA1, ABCG1↑; LC3II/LC3I↑, Beclin-1↑ | unknown |
Figure 5The schematic flowchart of diverse pathogenic mechanisms of AS and the intervention exerted by CHMs.